Pediatric Cancer

PEDIATRIC CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Does Larotrectinib Offer New Hope to Children With TRK Fusion-Positive Solid Tumors?

Because of the drug’s promising safety and efficacy, the first child was treated on trial only 9 months after the first adult with a TRK fusion was treated.
Recent Conference Highlights New Potential Targets for Pediatric Cancer Treatments

Advances in targeted therapy for pediatric patients were presented at the AACR Special Conference on Pediatric Cancer.

PEDIATRIC CANCER NEWS

A review published in Blood highlights new approaches that are being investigated to treat PCNSL bas

LIBRETTO-121: A Phase 1/2 Trial Investigating LOXO-292 in Pediatric Patients With Advanced Solid or Primary CNS Tumors

June 25, 2019

Childhood cancer survivors exposed to therapies that cause pulmonary dysfunction are associated with

Phase 1/2 Study of Durvalumab and Tremelimumab in Pediatric Cancer

June 25, 2019

Long-Term Follow-Up for Late Effects in Survivors of Childhood and Adolescent/Young Adult Cancers

Overall Cancer Survival Rates Up Among Adolescents, Young Adults

June 19, 2019

Childhood cancer survivors exposed to therapies that cause pulmonary dysfunction are associated with

Higher Risk for Cancer, Mortality Seen With Pediatric-Onset IBD

May 14, 2019

A large, long-term study found a 97% event-free survival rate at 18 months.

Less Postoperative Chemotherapy for Pediatric Hepatoblastoma Has No Effect on Disease Control

April 18, 2019

Next post in Pediatric Cancer

Long-Term Follow-Up for Late Effects in Survivors of Childhood and Adolescent/Young Adult Cancers

Overall Cancer Survival Rates Up Among Adolescents, Young Adults